Studies Comparing 18F-NaF with Other Radiotracers

Meta-analysis of 18F-NaF in both benign and malignant lesions (5)Patient-based pooled96%98%
Lesion-based pooled97%98%
Bone metastasis detection in hepatocellular carcinoma (37)99mTc-MDP73.3%79.2%86.8%61.3%75.4%
18F-NaF PET/CT93.3%100%100%88.9%97.5%
Bone metastasis detection in urinary bladder cancer (36)99mTc-MDP82.35%64.51%56%86.95%70.83%
99mTc-MDP SPECT/CT88.23%74.19%65.21%92%79.16%
18F-NaF PET/CT100%87.09%80.95%100%91.66%
High-risk prostate cancer (35)99mTc-MDP70%57%64%55%
99mTc-MDP SPECT/CT92%82%86%90%
18F-NaF PET100%62%74%100%
18F-NaF PET/CT100%100%100%100%
Spine metastasis in prostate cancer (42)99mTc-MDP51%82%86%43%61%
18F-NaF PET/CT93%54%82%78%81%
18F-fluoromethylcholine PET/CT85%91%95%75%87%
Bone metastasis detection in head and neck cancer (60)18F-NaF PET/CT69.4%
18F-FDG PET/CT57.1%
Detection of skull-base invasion in nasopharyngeal cancer (62)18F-NaF PET/CT100%94.7%96.3%100%97.8%
18F-FDG PET/CT65.4%100%100%67.9%80%
Detection of bone metastasis in nasopharyngeal cancer (62)18F-NaF PET/CT98.3%65.7%
18F-FDG PET/CT42.9%97.1%
  • Sn = sensitivity; Sp = specificity; PPV = positive predictive value; NPV = negative predictive value; Ac = accuracy.